CPHI - China Pharma files plan of compliance to NYSE American

• China Pharma ( NYSE: CPHI ) said it submitted a plan of compliance to the NYSE American to address a deficiency in the company's stockholders' equity.
• In June, the company received a letter from the exchange noting that it was not in compliance with continued listing standards.
• The company had to submit a plan of compliance by July 15, which the company did on the date, according to the July 18 press release.
• "The staff of the NYSE American indicated that they could accept the plan of compliance. During the next 18 months grace period or by December 15, 2023, we will actively supply additional information as required by the Exchange, implement the plan and strive to regain compliance on stockholders' equity as required by the Exchange listing requirement under as soon as possible," said China Pharma's Chairman and CEO  Zhilin Li.

For further details see: